The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.
Tobias W KlausenHenrik GregersenNiels AbildgaardNiels Frost AndersenUlf Christian FrølundPeter GimsingCarsten HellebergAnnette Juul VangstedPublished in: Leukemia (2018)